- Home
- TTAN vs ROIV Comparison
TTAN vs ROIV Comparison
Compare TTAN & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TTAN
- ROIV
- Stock Information
- Founded
- TTAN 2012
- ROIV 2014
- Country
- TTAN United States
- ROIV United Kingdom
- Employees
- TTAN N/A
- ROIV N/A
- Industry
- TTAN
- ROIV Biotechnology: Pharmaceutical Preparations
- Sector
- TTAN
- ROIV Health Care
- Exchange
- TTAN NYSE
- ROIV Nasdaq
- Market Cap
- TTAN 8.4B
- ROIV 8.4B
- IPO Year
- TTAN 2024
- ROIV N/A
- Fundamental
- Price
- TTAN $119.89
- ROIV $10.15
- Analyst Decision
- TTAN Buy
- ROIV Buy
- Analyst Count
- TTAN 14
- ROIV 4
- Target Price
- TTAN $115.54
- ROIV $17.50
- AVG Volume (30 Days)
- TTAN 544.3K
- ROIV 8.0M
- Earning Date
- TTAN 03-13-2025
- ROIV 05-29-2025
- Dividend Yield
- TTAN N/A
- ROIV N/A
- EPS Growth
- TTAN N/A
- ROIV N/A
- EPS
- TTAN N/A
- ROIV N/A
- Revenue
- TTAN $771,878,000.00
- ROIV $122,585,000.00
- Revenue This Year
- TTAN $19.04
- ROIV N/A
- Revenue Next Year
- TTAN $13.40
- ROIV N/A
- P/E Ratio
- TTAN N/A
- ROIV N/A
- Revenue Growth
- TTAN 25.64
- ROIV 140.04
- 52 Week Low
- TTAN $79.81
- ROIV $8.73
- 52 Week High
- TTAN $123.48
- ROIV $13.06
- Technical
- Relative Strength Index (RSI)
- TTAN N/A
- ROIV 50.07
- Support Level
- TTAN N/A
- ROIV $9.90
- Resistance Level
- TTAN N/A
- ROIV $10.26
- Average True Range (ATR)
- TTAN 0.00
- ROIV 0.47
- MACD
- TTAN 0.00
- ROIV 0.06
- Stochastic Oscillator
- TTAN 0.00
- ROIV 92.81
About TTAN SERVICETITAN INC
ServiceTitan Inc is an end-to-end technology platform built for contractors to transform the performance of their businesses. The Company's platform provides business owners, technicians, customer service representatives and other key office staff with technology tools designed to help customers grow revenue, drive operational efficiencies, deliver a superior end-customer experience and monitor key business drivers in real-time.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.